Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Impact of Ad Exposure Frequency on Perception and Mental Processing of Risks and Benefit Information in Direct-to-Consumer Prescription Drug Ads

Краткое содержание

The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Impact of Ad Exposure Frequency on Perception and Mental Processing of Risks and Benefit Information in Direct-to-Consumer Prescription Drug Ads" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.